Alkem Laboratories is one of India’s largest generic and specialty pharmaceutical company. Also, it has consistently been ranked amongst the top ten pharmaceutical companies in India. Its portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged. Some part of its revenue is generated via offshore sales. The company has manufacturing facilities at multiple locations in India and the United States of America. Its upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.

Business area of the company

The company is one of India’s foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.

Alkem Laboratories Ltd.

Lupin Ltd.

Biocon Ltd.

Zydus Lifesciences Ltd.

Abbott India Ltd.

Gland Pharma Ltd.

Aurobindo Pharma Ltd.

Laurus Labs Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Ipca Laboratories Ltd.

Pfizer Ltd.

Piramal Enterprises Ltd.

Torrent Pharmaceuticals Ltd.

Ajanta Pharma Ltd.

JB Chemicals & Pharmaceuticals Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	37,243 Cr		EPS	84.0		High	3156.65
Stock P/E	37.1		Net Profit Margin	11.3		Low	3045.55

Market Cap	37,243 Cr	ROE	19.8%
P/E Ratio(TTM)	37.1	EPS(TTM)	109.2
P/B Ratio	4.1	Dividend Yield	1.1%
Industry P/E	65.5	Book Value	768.3
		Face Value	2.0

ALKEM